UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of November, 2024
Commission File No. 001-39621
OPTHEA LIMITED
(Translation of registrant’s name into English)
Level 4
650 Chapel Street
South Yarra, Victoria, 3141
Australia
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
EXHIBIT INDEX
Exhibit |
|
Description |
99.1 |
|
Press Release - Opthea's Wet AMD Program Featured at Ophthalmology Events |
|
|
|
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
|
OPTHEA LIMITED |
|
|
(Registrant) |
|
|
|
|
|
By: |
/s/ Frederic Guerard |
|
Name: |
Frederic Guerard |
|
Title: |
Chief Executive Officer |
Date: 11/12/2024
Exhibit 99.1
ASX, Nasdaq and Media Release
November 12, 2024
Opthea’s Wet AMD Program Featured at Ophthalmology Events
17 Congress of the Asia-Pacific Vitreo-Retina Society, November 22 - 24, 2024
Ophthalmology Innovation Summit XIV, November 23, 2024
Melbourne, Australia, and Princeton, NJ, US, November 12, 2024 -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Opthea and sozinibercept will be highlighted during two upcoming Ophthalmology conferences.
Conference details are as follows:
The 17th Congress of the Asia-Pacific Vitreo-Retina Society (APVRS)
Session: Rapid Fire 4 – Retina (Medical & Surgical)
Timing: Friday, November 22, 2024, 3:15 – 3:20 PM Singapore time (GMT+8)
Presentation: Intravitreal Sozinibercept (anti-VEGF-C/-D ‘trap’) Combined with Ranibizumab for the Treatment of Polypoidal Choroidal Vasculopathy: A Predefined Phase 2b Subgroup Analysis
Presenter: Gregg T. Kokame, MD, MMM, FASRS
Abstract: https://2024.apvrs.org/abstract/?code=200963
Gregg T. Kokame, MD, MMM, FASRS, will present data from a predefined subgroup of the sozinibercept Phase 2b wet AMD trial related to patients with polypoidal choroidal vasculopathy (PCV), measured at 24 weeks. Data from this subgroup show that patients treated with a combination of sozinibercept and ranibizumab experienced significantly better visual and anatomic outcomes compared to ranibizumab alone.
APVRS, themed Transforming Retinal Disease Management with Technology, gathers a distinguished international faculty of top specialists in vitreo-retina to share their expertise and experience. The scientific program will focus on exciting areas such as novel surgical innovations
and therapies, and latest advances in imaging and research.
Ophthalmology Innovation Summit XIV (OIS)
Session: Retina Innovation Showcase
Timing : Saturday, November 23, 2024, 11:15 AM – 12:50 PM PT
Presenter: Frederic Guerard, PharmD, CEO, Opthea
Agenda: https://ois.net/ois-xiv-agenda/
The Ophthalmology Innovation Summit connects clinical, corporate, and capital leaders to drive the ophthalmic market forward. It showcases groundbreaking advancements and clinical insights in both anterior and posterior ophthalmology segments and offers the opportunity to learn, network and collaborate.
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.
To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.
Authorized for release to ASX by Frederic Guerard, PharmD, CEO
Investor Inquiries |
Join our email database to receive program updates: |
PJ Kelleher LifeSci Advisors LLC Email: pkelleher@lifesciadvisors.com Phone: 617-430 7579
Media Inquiries
Silvana Guerci-Lena NorthStream Global Partners silvana@nsgpllc.com |
Tel: +61 (0) 3 9826 0399 Email: info@opthea.com Web: www.opthea.com
Source: Opthea Limited |